We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Found for Sporadic Breast Cancer

By Biotechdaily staff writers
Posted on 10 Dec 2003
A study suggests that a gene newly named EMSY shuts down the action of functional BRCA2 to fuel cancer's development and also has a role in repairing damaged DNA.

Inheriting faulty BRCA genes can trigger hereditary breast and ovarian cancer but the role of these genes in sporadic cancer has not been known. More...
The EMSY gene is thought to be the answer to why breast and ovarian cancers develop in women who have no family history of these cancers. When researchers analyzed the gene sequence of 551 breast and 360 ovarian tumors, they found extra copies of EMSY in 13% of breast cancers and 17% of ovarian cancers, but none in normal tissue and hardly ever in other forms of cancer. Cancer patients who have extra copies of the EMSY gene have a lower survival rate, an average of 6.4 years, compared to 14 years for other patients.

"Discovering such an important new gene is very exciting and gives us the piece in the jigsaw we've been looking for,” said Professor Tony Kouzarides, who led the project at Wellcome Trust and Cancer Research Institute (Cambridge, UK; www.welc.cam.ac.uk). "We'll now have a much more sophisticated image of the genetic changes triggering breast and ovarian cancer in women who haven't inherited a high risk of cancer but develop it anyway.”




Related Links:
Wellcome Trust

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Hematology Consumables
Bioblood Devices
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.